ArticleInternational journal of ophthalmology2025
Choroidopathy in patients with systemic lupus erythematosus using enhanced depth imaging spectral domain optical coherence tomography and optical coherence tomography angiography.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Retinal Vaso-Occlusive Complications Associated with Systemic Lupus Erythematosus: A Systematic Review of Clinical Presentation and Visual Outcomes.Mediterranean journal of rheumatology · 2026Article
- Choroidal thickness changes in patients with systemic lupus erythematosus treated with hydroxychloroquine using three dimensional maps.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the choroidopathy in patients with systemic lupus erythematosus (SLE) using enhanced depth imaging spectral domain optical coherence tomography (EDI SD-OCT) and optical coherence tomography angiography (OCTA).
methodsA total of 74 patients with SLE and 40 healthy volunteers were included in this cross-sectional study. SLE patients were further divided into three subgroups based on clinical and blood biochemistry findings. Ocular parameters obtained on ophthalmologic examination and optical imaging (EDI SD-OCT and OCTA) included the best corrected distance visual acuity (logMAR CDVA), subfoveal choroidal thickness (SCT), choroidal vascularity index (CVI) and vessel density (VD) of superficial capillary plexus (SCP) and deep capillary plexus (DCP).
resultsSLE patients had significantly lower values for CVI and VD of DCP (DVD) than control subjects. Amongst SLE patients, gender and chloroquine dose were found to be independent determinants of CVI while age predicted SCT. Steroid dose was a significant predictor for foveal VD of SCP (SVD), chloroquine dose for parafoveal SVD, gender for total DVD, and gender and steroid dose for perifoveal DVD. No correlation of logMAR CDVA and SCT was noted between SLE patients and control subjects. No correlation of SCT was noted with disease duration, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, hydroxychloroquine (HCQ) dose or steroid dose. No correlation of CVI was noted with patient age, disease duration, SLEDAI score, HCQ dose or steroid dose. No significant difference was noted between SLE subgroups in terms of any of the ocular parameters studied.
conclusionThe findings reveal the presence of ocular findings suggestive of early onset choroidopathy on EDI SD-OCT and OCTA in SLE patients, in the absence of ocular manifestations or active disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.